Cover Image

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial

Immune responses to 13-valent pneumococcal conjugate vaccine (PCV13) and quadrivalent inactivated influenza vaccine (QIV) in older adults may vary with coadministration and previous pneumococcal polysaccharide vaccination. This study assessed safety and noninferiority of immune responses to coadmini...

Full description

Saved in:

Bibliographic Details
Main Authors:	Allison R. Thompson (Author), Nicola P. Klein (Author), H. Jackson Downey (Author), Scott Patterson (Author), Vani Sundaraiyer (Author), Wendy Watson (Author), Keri Clarke (Author), Kathrin U. Jansen (Author), Shite Sebastian (Author), William C. Gruber (Author), Daniel A. Scott (Author), Beate Schmöele-Thoma (Author)
Format:	Book
Published:	Taylor & Francis Group, 2019-02-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
by: Beate Schmoele-Thoma, et al.
Published: (2019)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
by: Christine Juergens, et al.
Published: (2018)

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy
by: Mark A. Fletcher, et al.
Published: (2024)

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial
by: Bhagirath B. Solanki, et al.
Published: (2017)

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease
by: Charu Sabharwal, et al.
Published: (2022)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
by: Erica Chilson, et al.
Published: (2020)

Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age
by: Raul E. Isturiz, et al.
Published: (2018)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
by: Michael W. Simon, et al.
Published: (2023)

Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
by: Miguel Gouveia, et al.
Published: (2019)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
by: Thundon Ngamprasertchai, et al.
Published: (2023)

Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
by: Min-Joo Choi, et al.
Published: (2018)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
by: Tatiane E. Hirose, et al.
Published: (2015)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
by: Johnna Perdrizet, et al.
Published: (2021)

Higher valent Pneumococcal Conjugate Vaccines: is it a roller coaster?
by: Godwin Oligbu
Published: (2020)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019)

Impact of 10-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children up to two years of age in Brazil
by: Indianara Maria Grando, et al.
Published: (2015)

Efficacy of usage of pneumococcal 7-valent vaccine in prophylaxis of pneumococcal infection in Novosibirsk children from risk groups
by: O. A. Beletskaya, et al.
Published: (2013)

INCIDENCE OF PNEUMOCOCCAL INFECTION IN THE WESTERN EUROPEAN COUNTRIES. INTERNATIONAL EXPERIENCE IN USING SEVEN-VALENT PNEUMOCOCCAL CONJUGATED VACCINE
by: article editorial
Published: (2008)

PNEUMOCOCCAL INFECTION. IMMUNIZATION BY A 7-VALENT CONJUGATED PNEUMOCOCCAL VACCINE OF CHILDREN BORN TO HIV-POSITIVE WOMEN
by: L.Yu Afoninа, et al.
Published: (2011)

INCIDENCE OF PNEUMOCOCCAL INFECTION IN THE WESTERN EUROPEAN COUNTRIES. INTERNATIONAL EXPERIENCE IN USING SEVEN-VALENT PNEUMOCOCCAL CONJUGATED VACCINE
by: article editorial
Published: (2008)

PNEUMOCOCCAL INFECTION. IMMUNIZATION BY A 7-VALENT CONJUGATED PNEUMOCOCCAL VACCINE OF CHILDREN BORN TO HIV-POSITIVE WOMEN
by: L.Yu Afoninа, et al.
Published: (2011)

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
by: R. Reyburn, et al.
Published: (2022)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review
by: Yuanze Du, et al.
Published: (2023)

Nasopharyngeal pneumococcal carriage in healthy Turkish children after 13-valent conjugated pneumococcal vaccine implementation in the national immunization program
by: Saliha Kanık Yüksek, et al.
Published: (2020)